title: Nemifitide. Innapharma.
abstract: Nemifitide is a peptide under development by Innapharma for the potential treatment of depression. By June 2001, the first phase II trial of nemifitide in moderate to severely depressed individuals had been completed and in February 2003, Innapharma anticipated that phase III trials would commence later that year.
authors: Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil, Switzerland. Jasper.Dingemanse@actelion.com
authors: Jasper
authors: J
authors: Dingemanse
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D009842:Oligopeptides / Q000737:chemistry / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D015507:Drugs, Investigational; D009842:Oligopeptides; C406668:nemifitide ditriflutate